PreveCeutical Medical (Seite 6)
eröffnet am 04.10.18 20:07:39 von
neuester Beitrag 06.05.24 23:44:20 von
neuester Beitrag 06.05.24 23:44:20 von
Beiträge: 879
ID: 1.289.874
ID: 1.289.874
Aufrufe heute: 65
Gesamt: 30.218
Gesamt: 30.218
Aktive User: 0
ISIN: CA74141E1043 · WKN: A2DU8Q
0,0170
EUR
+25,93 %
+0,0035 EUR
Letzter Kurs 22:06:03 Lang & Schwarz
Neuigkeiten
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7400 | +36,63 | |
| 3,5100 | +27,64 | |
| 0,7450 | +26,27 | |
| 0,6000 | +20,00 | |
| 2,3500 | +14,63 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5998 | -21,52 | |
| 2,4325 | -29,75 | |
| 2,5900 | -32,11 | |
| 2,8000 | -46,67 | |
| 2,4100 | -51,51 |
Beitrag zu dieser Diskussion schreiben
Feedback
Es tut sich nichts... Denke wir schauen 2030 nochmal ins Depot
Antwort auf Beitrag Nr.: 73.982.324 von wasi1970 am 09.06.23 20:44:01Oder es macht einen wahnsinnig 😅😅😅
Das Teil hier ist der Wahnsinn
Trading Spotlight
Antwort auf Beitrag Nr.: 73.915.100 von wasi1970 am 26.05.23 19:02:26Ich denke, dass kommt auf einen Schlag! Sobald ein Produkt nun im Markt ist und diverse Erfolge feiert oder ein großer massiv einsteigt. Von einem langsamen Anstieg ist meiner Meinung nach nicht auszugehen.
Zündet Sie... Oder zündet Sie nicht... Das ist hier die Frage... Gute Nacht
Dual Gene Therapy
TARGETING TYPE 2 DIABETES AND OBESITY
Over five years of multi-disciplinary research, Dr. Parekh’s team has collectively generated convincing results in models of this disease, using Smart siRNA and a Tissue Targeted Bio-responsive Carrier System. This program paves the way for preclinical evaluation of proprietary chemistry toward the single gene target implicated in type 2 diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.
“With diabetes, over-production of a particular protein molecule has been identified and purposed to be responsible for the key drivers of diabetes and obesity, starting patient on an inevitable journey of significant co-morbidity and increased rates of mortality.
PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels; this would in turn help our cells to absorb glucose, thus reducing blood sugar levels and prevent the body from storing excessive fat from our diet. Thus gene-silencing does not represent a mere management for diabetes and obesity, it represents the potential for a bona fide cure or, in cases where patients have a pre-disposition to diabetes or are in the pre-diabetes state, it can be applied as a ‘PreveCeutical’ to halt progress to the full-blown disease.
This is not merely theoretical. Five years of painstaking work has gone into this initiative and management has already taken this research through the proof-of-concept stage in cellular models of diabetes and obesity.” – Chief Research Officer: Dr. Harry Parekh, PhD, MRPharmS
TARGETING TYPE 2 DIABETES AND OBESITY
Over five years of multi-disciplinary research, Dr. Parekh’s team has collectively generated convincing results in models of this disease, using Smart siRNA and a Tissue Targeted Bio-responsive Carrier System. This program paves the way for preclinical evaluation of proprietary chemistry toward the single gene target implicated in type 2 diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.
“With diabetes, over-production of a particular protein molecule has been identified and purposed to be responsible for the key drivers of diabetes and obesity, starting patient on an inevitable journey of significant co-morbidity and increased rates of mortality.
PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels; this would in turn help our cells to absorb glucose, thus reducing blood sugar levels and prevent the body from storing excessive fat from our diet. Thus gene-silencing does not represent a mere management for diabetes and obesity, it represents the potential for a bona fide cure or, in cases where patients have a pre-disposition to diabetes or are in the pre-diabetes state, it can be applied as a ‘PreveCeutical’ to halt progress to the full-blown disease.
This is not merely theoretical. Five years of painstaking work has gone into this initiative and management has already taken this research through the proof-of-concept stage in cellular models of diabetes and obesity.” – Chief Research Officer: Dr. Harry Parekh, PhD, MRPharmS
BIG NEWS!
Wenn die Studie nun greift, zündet die Rakete!
Jetzt heißt es noch einmal richtig nachkaufen! 🔥🔥🔥
Wenn die Studie nun greift, zündet die Rakete!
Jetzt heißt es noch einmal richtig nachkaufen! 🔥🔥🔥
Dual Gene Therapy
TARGETING TYPE 2 DIABETES AND OBESITY
Over five years of multi-disciplinary research, Dr. Parekh’s team has collectively generated convincing results in models of this disease, using Smart siRNA and a Tissue Targeted Bio-responsive Carrier System. This program paves the way for preclinical evaluation of proprietary chemistry toward the single gene target implicated in type 2 diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.
“With diabetes, over-production of a particular protein molecule has been identified and purposed to be responsible for the key drivers of diabetes and obesity, starting patient on an inevitable journey of significant co-morbidity and increased rates of mortality.
PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels; this would in turn help our cells to absorb glucose, thus reducing blood sugar levels and prevent the body from storing excessive fat from our diet. Thus gene-silencing does not represent a mere management for diabetes and obesity, it represents the potential for a bona fide cure or, in cases where patients have a pre-disposition to diabetes or are in the pre-diabetes state, it can be applied as a ‘PreveCeutical’ to halt progress to the full-blown disease.
This is not merely theoretical. Five years of painstaking work has gone into this initiative and management has already taken this research through the proof-of-concept stage in cellular models of diabetes and obesity.” – Chief Research Officer: Dr. Harry Parekh, PhD, MRPharmS
TARGETING TYPE 2 DIABETES AND OBESITY
Over five years of multi-disciplinary research, Dr. Parekh’s team has collectively generated convincing results in models of this disease, using Smart siRNA and a Tissue Targeted Bio-responsive Carrier System. This program paves the way for preclinical evaluation of proprietary chemistry toward the single gene target implicated in type 2 diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.
“With diabetes, over-production of a particular protein molecule has been identified and purposed to be responsible for the key drivers of diabetes and obesity, starting patient on an inevitable journey of significant co-morbidity and increased rates of mortality.
PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels; this would in turn help our cells to absorb glucose, thus reducing blood sugar levels and prevent the body from storing excessive fat from our diet. Thus gene-silencing does not represent a mere management for diabetes and obesity, it represents the potential for a bona fide cure or, in cases where patients have a pre-disposition to diabetes or are in the pre-diabetes state, it can be applied as a ‘PreveCeutical’ to halt progress to the full-blown disease.
This is not merely theoretical. Five years of painstaking work has gone into this initiative and management has already taken this research through the proof-of-concept stage in cellular models of diabetes and obesity.” – Chief Research Officer: Dr. Harry Parekh, PhD, MRPharmS
Durchsuchen
